FINWIRES · TerminalLIVE
FINWIRES

HKG:2315

3 stories mentioning HKG:2315Updated just now

Every FINWIRES story that references HKG:2315, newest first.

Asia

Biocytogen Pharmaceuticals Expects H1 Profit to Soar by Up to 413%; Shares Up 10%

Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) expects its net profit attributable to owners in the first half to surge by between 392% and 413% year on year to 236.1 million yuan to 246.1 million yuan, according to a Hong Kong bourse filing on Thursday.The Chinese pharmaceutical company's Shanghai shares jumped 10%, while Hong Kong shares rose 4% during the midday trade.The attributable profit a year earlier was almost 48 million yuan, with earnings per share of 0.12 yuan.Revenue is expected to jump by between 51% and 52% to 936.4 million yuan to a range of 936.4 million yuan to 946.4 million yuan from the year-ago revenue of 621 million yuan.

HKG:2315SHA:688796
Asia

Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) scored a legal win in China after a court dismissed a claim made by HBM (HKG:2142) subsidiary Harbour Antibodies.Specifically, the Shanghai Intellectual Property Court made a first-instance judgment to dismiss Harbour Antibodies' allegation that Biocytogen's RenNano platform and related antibody products infringed on its exclusively licensed invention patent ZL201210057668.0, according to a Monday filing.

Shanghai Composite^SZSEHKG:2315
Asia

Biocytogen Pharmaceuticals Turns to Profit in Q1

Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.

HKG:2315

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2315 in your portfolio
WheelAI
WheelAI
Analyze HKG:2315 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2315